| | Without DeVega | With DeVega |
|-------------|----------------|-------------|
| ≥Mod TR | 5 (7.9%) | 2 (3.7%) |
| 1 week | n=63 | n=53 |
| ≥Mod TR | 2 (2.6%) | 2 (2.9%) |
| 3 months | n=69 | n=77 |
| ≥Mod TR | 3 (3.2%) | 0 (0%) |
| 12 months | n=94 | n=63 |
| ≥Mod RV | 7 (9%) | 4 (6%) |
| dysfunction | n=77 | n=67 |
| 3 months | | |
| ≥Mod RV | 4 (4.3%) | 6 (9.7%) |
| dysfunction | n=94 | n=62 |
| 12 months | | |

Supplemental table 2. Percent of patients with greater than moderate TR and RV dysfunction who had OHT between 2013-2017 at Columbia University Medical

<u>Center.</u> At one year, 0 patients with DVA had significant TR, compared with 3 no DVA patients. TV dysfunction was similar between groups. Follow-up is variable. Values are absolute patient quantity, (% of total).